This extensive review summarizes clinical evidence on immunotherapy and targeted
therapy currently available for endometrial cancer (EC) and reports the results of the clinical …

Aim It has been suggested that chronic hyperinsulinemia from insulin resistance is involved
in the etiology of endometrial cancer (EC). We performed a systematic review and meta …

The focus of Berek and Hacker's for four editions has been on the application of basic and
clinical science to the clinical practice of gynecologic oncology. That approach has been …

BACKGROUND Metformin is an effective oral anti-hyperglycaemic drug used as first-line
medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing …

Obesity is the strongest risk factor for endometrial cancer (EC). To inform targeted screening
and prevention strategies, we assessed the impact of obesity and subsequent bariatric …

OBJECTIVE: To review the role played by insulin resistance in the development of
endometrial cancer. METHODS: Relevant manuscripts and studies were searched on …

Diabetic mellitus remains prevalent in the world. It is a condition of hyperglycemia which are
at risk of macrovascular and microvascular complications. One of diabetes complications is …

BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers
in diabetic patients. Metformin‐induced inhibition of cancer cell proliferation has been …

Background Previous studies have suggested that metformin may be useful for preventing
and treating endometrial cancer (EC), while the results have been inconsistent. This …

Background: Preclinical studies in endometrial cancer (EC) show that metformin reduces
cellular proliferation by PI3K-AKT-mTOR inhibition. We tested the hypothesis that short-term …